



CLART® STIs - A&B

Detecting microorganisms causing urogenital tract infections

MICROORGANISMS DETECTED :

BACTERIA

- *Chlamydia trachomatis**
- *Neisseria gonorrhoeae**
- *Mycoplasma genitalium**
- *Mycoplasma hominis*
- *Ureaplasma parvum*
- *Ureaplasma urealyticum*
- *Treponema pallidum*
- *Haemophilus ducreyji*

VIRUSES

- HSV1
- HSV2

PARASITE

- *Trichomonas vaginalis**

FUNGI

- *Candida albicans*
- *Candida glabrata*
- *Candida krusei*
- *Candida dubliniensis*
- *Candida guilliermondii*
- *Candida parapsilosis*
- *Candida tropicalis*

* Microorganism analyzed with CLART®STI A, remaining microorganism are analyzed with CLART®STI B

MAIN ADVANTAGES OF MOLECULAR DETECTION OF MICROORGANISMS CAUSING STI :

Molecular diagnostic techniques provide greater sensitivity and standardize the multiple methodologies used so far for the detection of those microorganism causing urogenital tract infections.

Moreover, molecular diagnostics techniques reduce the drawbacks and limitations of conventional detection methods as:

- ▶ Low sensitivity shown by cultures.
- ▶ Antibody titers variations due to antiviral treatment.

FEATURES :

- Both kits have been validated for automatic DNA extraction from urine samples and swabs (vaginal, cervical, endocervical, urethral and rectal).
- High sensitivity and specificity.
- No previous culture required.
- Three quality controls included per sample:
 - **Genomic DNA control:** validates the extraction performance.
 - **Amplification control:** avoids false negative results.
 - **Biotin markers:** check the proper performance of the visualization reagents provided with the kit.
- Each target is detected in triplicate avoiding unspecific bindings.

- Results are obtained within a working day.
- Considerably reduction of turnaround time allowing the most effective therapy adjustment in the short term.
- Compatible with any GENOMICA automation system.

DATA MANAGEMENT :

- Automatic reading and interpretation of results (CAR®).
- User-friendly report format (html, bmp).
- Samples are analyzed individually and three complementary reports are generated.
- Every report generated can be stored, exported and printed.



REPORTING RESULTS :



► Report and image obtained by CAR® reader.



B4

Result view		AT code: 50516
CLART® STIs A		Rev. 16sc.3
Sample reference:	3	
Array ID:	000000050516 (C1)	
Analysis type:	tmb end point detection	
Date and time:	Fri Jan 14 15:25:36 2011	

Bacteria	Result	Controls
<i>Chlamydia trachomatis</i>	Negative	Passed
<i>Neisseria gonorroea</i>	Positive	Passed
<i>Treponema pallidum</i>	Negative	Passed
<i>Mycoplasma genitalium</i>	Negative	Passed

ORDERING REFERENCES AND CONTACT DETAILS :

CLART® STIs Amplification A

48 tests: CS-1112-48

CLART® STIs Amplification B

48 tests: CS-0213-48

CLART® STIs A / CLART® STIs B Visualization

48 tests: CS-1212-48

■ Parque Empresarial Alvento. Edificio B.
Vía de los Poblados, 1. 1ª Planta.
28033 Madrid (Spain).

■ Tel.: +34 91 674 89 90

■ Fax: +34 91 674 89 91

■ info.genomica@genomica.com

BIBLIOGRAPHY :

1. "Gardnerella, Trichomonas vaginalis, Candida, Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma urealyticum in the genital discharge of symptomatic fertile and asymptomatic infertile women". *New Microbiologica*, 33, 69-76, 2010.
2. "Global strategy for the prevention and control of sexually transmitted infections: 2006 -2015 : breaking the chain of transmission". WHO
3. "Sexually Transmitted Diseases in the United States, 2008 National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis". CDC.
4. "Persistent increase in the incidence of acute male urethritis diagnosed in general practices in France". *British Journal of General Practice* 2006; 56: 110-114.
5. "Mycoplasma genitalium presence, resistance and epidemiology in Greenland". *Int J Circumpolar Health* 2012, 71:18203